Ratings Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 06:49:34 2025-01-15 am EST			5-day change	1st Jan Change
984.90 ^INR	-1.52%		-1.59%	+1.36%

Jan. 10	Nomura Upgrades Zydus Lifesciences to Buy From Neutral, Adjusts Price Target to INR1,140 From INR1,030	MT
Jan. 07	CVS Health Unit to Include Zydus Lifesciences' Diabetes Medications in Template Formulary	MT

Summary: Zydus Lifesciences Limited

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Highlights: Zydus Lifesciences Limited

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analyst opinion has improved significantly over the past four months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses: Zydus Lifesciences Limited

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's enterprise value to sales, at 4.24 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings Chart: Zydus Lifesciences Limited

Source: Surperformance

ESG chart: Zydus Lifesciences Limited

Source: MSCI

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	ZYDUS LIFESCIENCES LIMITED				11.63B
	SUN PHARMACEUTICAL INDUSTRIES LTD.				49.1B
	OTSUKA HOLDINGS CO., LTD.				27.36B
	SANDOZ GROUP AG				18.47B
	CIPLA LIMITED				13.51B
	GLENMARK PHARMACEUTICALS LIMITED				4.94B
	ONO PHARMACEUTICAL CO., LTD.				4.86B
	GEDEON RICHTER				4.84B
	Average				16.84B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG MSCI

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

ESG

Environment

Social

Governance

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes